ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2843

The Relationship between Serum Urate Concentration and Incident Gout: An Individual Participant Data Analysis

Nicola Dalbeth1, Amanda Phipps-Green2, Christopher Frampton3, Tuhina Neogi4, William J. Taylor5 and Tony R. Merriman6, 1University of Auckland, Auckland, New Zealand, 2University of Otago, Dunedin, New Zealand, 3University of Otago, Christchurch, New Zealand, 4Boston University School of Medicine, Boston, MA, 5University of Otago, Wellington, New Zealand, 6Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Gout and uric acid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Metabolic and Crystal Arthropathies I: Gout Risk of Disease Activity, Cardiovascular Disease and Mortality

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Elevated serum urate concentration (hyperuricemia) is considered to be a key risk factor for developing gout.  However, the relationship between serum urate and incident gout is unclear, with variation in estimates of risk depending on different published studies.  We undertook the largest individual participant data analysis to date to examine the relationship between serum urate concentration and incident gout.

Methods: Publically available cohort studies with both baseline serum urate and incident gout data were identified through a systematic search of PubMed and the Database of Genotype and Phenotype, and individual participant data were extracted for analysis.  Kaplan-Meier plots were generated and the cumulative incidence of gout was calculated according to the baseline serum urate category.  We evaluated the relation of serum urate categories (<6mg/dL as referent group) to risk of gout using Cox proportional hazards modelling, adjusted for potential confounders (age, sex, ethnicity, cohort). 

Results: Four cohorts with publically available data were identified (Atherosclerosis Risk in Communities Study, Coronary Artery Risk Development in Young Adults Study, and the Original and Offspring cohorts of the Framingham Heart Study), with a total of 18,889 participants who were gout-free at baseline, mean (SD) 11.2 (4.2) years of follow-up, and 212,363 total patient-years included in the analysis.  The overall cumulative incidence (95% CI) of gout by 5 years was 1.1 (0.9-1.3)%, by 10 years was 2.4 (2.2-2.6)% and by 15 years was 3.2 (2.8-3.6)%.  The cumulative incidence at each time point varied according to baseline serum urate concentrations, with 15 year cumulative incidence (95% CI) ranging from 1.1 (0.9-1.4)% for <6mg/dL to 48.6 (30.5-66.6)% for 10mg/dL or more (Figure and Table).  Compared with baseline serum urate <6mg/dL, the adjusted hazard ratio (95% CI) for baseline serum urate 6.0-6.9 mg/dL was 2.7 (2.0-3.6), for 7.0-7.9 mg/dL was 6.6 (5.0-8.8), for 8.0-8.9 mg/dL was 14.9 (11.1-20.1), for 8.0-8.9 mg/dL was 29.7 (20.8-42.3), and for 10mg/dL or more was 64.0 (42.5-96.1).

Conclusion: Serum urate is a strong concentration-dependent predictor of incident gout. Nonetheless, only about half of those with serum urate concentrations of 10mg/dL or more develop gout over 15 years, implying a role for additional factors in the pathogenesis of gout and a long duration of hyperuricemia preceding the onset of clinical gout. This analysis provides cumulative incidence estimates to guide discussions with hyperuricemic individuals about their risk of developing gout over time. 

 


Disclosure: N. Dalbeth, Takeda, AstraZeneca, Abbvie, 9; A. Phipps-Green, None; C. Frampton, None; T. Neogi, None; W. J. Taylor, Pfizer Inc, 5; T. R. Merriman, Ardea Biosciences, 2.

To cite this abstract in AMA style:

Dalbeth N, Phipps-Green A, Frampton C, Neogi T, Taylor WJ, Merriman TR. The Relationship between Serum Urate Concentration and Incident Gout: An Individual Participant Data Analysis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-relationship-between-serum-urate-concentration-and-incident-gout-an-individual-participant-data-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-relationship-between-serum-urate-concentration-and-incident-gout-an-individual-participant-data-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology